Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Author:
Funder
Merck Sharp & Dohme Corp.
Merck & Co.
Inc.
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz135/28756641/mdz135.pdf
Reference27 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. Ovarian cancer;Jayson;Lancet,2014
3. Ovarian cancer;Matulonis;Nat Rev Dis Primers,2016
4. National Academies of Sciences, Engineering, and Medicine,2016
5. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer;Alvarez;Gynecol Oncol,2016
Cited by 436 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial;Gynecologic Oncology;2024-03
2. CD47—a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features;World Journal of Surgical Oncology;2024-02-06
3. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer;Critical Reviews in Oncology/Hematology;2024-02
4. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages;Frontiers in Immunology;2024-01-22
5. Characteristics of Ovarian Cancer Immune Cell Invasion and Bioinformatics to Predict the Effect of Immunotherapy;Hormone and Metabolic Research;2024-01-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3